Significant pain reduction for post-shingles patients

April 01, 2003

Honolulu, HI - April 1, 2003 -- NeurogesX, Inc. today announced Phase II results of a treatment for post-shingles pain, a severe pain condition that affects an estimated 400,000 Americans. The study results demonstrated that a single dose of a capsaicin-containing dermal patch provided a 33% reduction in pain scores over the course of four weeks, compared to 4% with control treatment. The results of the clinical trial were disclosed at a late-breaking science presentation made today at the American Academy of Neurology's annual meeting by Dr. Misha-Miroslav Backonja, an investigator in the study and Director of Research and Education of the University of Wisconsin Pain Treatment Center in Madison, Wisconsin.

"The study demonstrates that long-term pain relief may be provided by a single application of high-concentration capsaicin patches," said Dr. Backonja. "Importantly, because the patch-based treatment is localized, the systemic side effects of traditional treatments may be avoided." Despite expected pain increases during the procedure due to the pungent nature of capsaicin, overall tolerability was good. Dr. Backonja said no safety concerns were identified. A plasma sample analysis of patients confirmed the lack of systemic capsaicin absorption.

Postherpetic Neuralgia
Every year, nearly 1 million Americans get shingles, a condition caused by varicella-zoster virus, the virus that also causes chickenpox. The condition usually results in a rash, blistering and, in many cases, severe pain. Many patients continue to have severe pain even after the rash disappears. This condition is called postherpetic neuralgia. It often persists for many years. Most current pain treatments for this pain syndrome require multiple doses each day and can cause side effects such as fatigue, light-headedness, fluid retention, constipation or dry mouth.

Capsaicin's Pain Relief Impact
Capsaicin, the pungent ingredient in hot chili peppers, activates certain receptors expressed by nerve fibers that specialize in the detection of painful stimuli. It is believed that the topical application of high doses of capsaicin can cause these capsaicin-sensitive nerve fibers to stop functioning. To the extent that these capsaicin-sensitive nerve fibers are involved in pain transmission, topically applied capsaicin could bring about a reduction in pain. For this reason, low-concentration capsaicin creams have been used with varying success for the treatment of postherpetic neuralgia and other pains. However, usage of these creams has been limited by the pain and inconvenience caused by the requirement for prolonged application several times a day, for weeks. The study reported on today used high-concentration capsaicin patches in a single one-hour application and provided pain reduction for four weeks.

Single Application Treatment Delivers Pain Relief without Safety Problems
The Phase II study for what NeurogesX calls NGX-4010 was a double-blind, randomized controlled, multi-center study evaluating the tolerability, safety, and efficacy of high-concentration capsaicin patches in the treatment of postherpetic neuralgia. Forty-four patients at nine centers in the United States were given a single treatment and then followed for four weeks.

The treatment procedure consisted of a single application of a topical non-prescription anesthetic for one hour, followed by a one-hour patch application on the most painful area, up to a maximum of 1000 cm2. The control group received a low-concentration capsaicin patch.

Patients recorded their pain intensity twice daily on an 11-point numerical scale. The primary efficacy endpoint was the change from baseline in morning/evening average pain (days 8 - 28).

In today's "Late Breaking Science" session, Dr. Backonja discussed the study results in an oral presentation.

Forty-two percent of patients in the active group experienced a pain decrease of 33 percent or more, compared to 8 percent in the control group. Pain decreases in the active group were noted on the first day after the procedure and remained stable throughout the four-week observation period. "As a purely local treatment without the potential for systemic side effects, high-concentration capsaicin patches could be a very effective and safe treatment alternative for patients suffering from postherpetic neuralgia," said Thorsten von Stein, M.D., Ph.D., Vice President of Clinical Development at NeurogesX, Inc., the company that sponsored the multi-center study.

Further Studies in Pain Treatment
NeurogesX said it will begin pivotal studies of NGX-4010 in April 2003. The company is also in the process of developing additional medicines for other pain syndromes, including the pain caused by tissue injury.
About NeurogesX
NeurogesX (neur-o-GEE-six) is a privately held specialty pharmaceutical company focusing on the development of products for the treatment of nerve signaling disorders. The company's initial products are focused on the treatment of chronic and acute pain. The company has raised $30 million in total equity investments since its first funding round in June 2000. Investors include Alta Partners, ARCH Venture Partners, Montreux Equity Partners, Grove Street Advisors for CalPERS, TIAA (Teachers Insurance and Annuity Association), Duke University, University of North Carolina and Walden International

For more information about NeurogesX, see its website,

NeurogesX is a trademark of NeurogesX, Inc.
All other trademarks and registered trademarks are those of their respective companies

Additional Contact:
Wendye Robbins, M.D.
NeurogesX, Inc.

Jackman Communications

Related Pain Articles from Brightsurf:

Pain researchers get a common language to describe pain
Pain researchers around the world have agreed to classify pain in the mouth, jaw and face according to the same system.

It's not just a pain in the head -- facial pain can be a symptom of headaches too
A new study finds that up to 10% of people with headaches also have facial pain.

New opioid speeds up recovery without increasing pain sensitivity or risk of chronic pain
A new type of non-addictive opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System accelerates recovery time from pain compared to morphine without increasing pain sensitivity, according to a new study published in the Journal of Neuroinflammation.

The insular cortex processes pain and drives learning from pain
Neuroscientists at EPFL have discovered an area of the brain, the insular cortex, that processes painful experiences and thereby drives learning from aversive events.

Pain, pain go away: new tools improve students' experience of school-based vaccines
Researchers at the University of Toronto and The Hospital for Sick Children (SickKids) have teamed up with educators, public health practitioners and grade seven students in Ontario to develop and implement a new approach to delivering school-based vaccines that improves student experience.

Pain sensitization increases risk of persistent knee pain
Becoming more sensitive to pain, or pain sensitization, is an important risk factor for developing persistent knee pain in osteoarthritis (OA), according to a new study by researchers from the Université de Montréal (UdeM) School of Rehabilitation and Hôpital Maisonneuve Rosemont Research Centre (CRHMR) in collaboration with researchers at Boston University School of Medicine (BUSM).

Becoming more sensitive to pain increases the risk of knee pain not going away
A new study by researchers in Montreal and Boston looks at the role that pain plays in osteoarthritis, a disease that affects over 300 million adults worldwide.

Pain disruption therapy treats source of chronic back pain
People with treatment-resistant back pain may get significant and lasting relief with dorsal root ganglion (DRG) stimulation therapy, an innovative treatment that short-circuits pain, suggests a study presented at the ANESTHESIOLOGY® 2018 annual meeting.

Sugar pills relieve pain for chronic pain patients
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology.

Peripheral nerve block provides some with long-lasting pain relief for severe facial pain
A new study has shown that use of peripheral nerve blocks in the treatment of Trigeminal Neuralgia (TGN) may produce long-term pain relief.

Read More: Pain News and Pain Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to